Metoprolol in the treatment of hypertension with paroxysmal atrial fibrillation in 30 cases.doc

 PAGE \* MERGEFORMAT 10 Metoprolol in the treatment of hypertension with paroxysmal atrial fibrillation in 30 cases [Abstract] Objective To observe hypertension with paroxysmal atrial fibrillation (AF patients, metoprolol (-blockers 1 year of treatment, target blood pressure control and the efficacy of maintaining sinus rhythm. Methods of hypertension 30 patients with paroxysmal AF, aged 40 to 69 years, mean (50 + -17 years old. including 19 males and 11 females. metoprolol oral dose of 50 ~ 100mg / d, 12-month course of treatment. The patients were followed up at 3,6,12 months, with the dynamic electrocardiogram (Holter AF episodes observed by echocardiography left atrial diameter (LAD, with the mercury sphygmomanometer cuff observe standards of blood pressure, before and after treatment to do its own control. Results LAD significantly less than before treatment, number of episodes of paroxysmal AF was significantly lower than before treatment. Conclusion AF metoprolol for hypertension with blood pressure control targets in the same time, effectively reduce the onset of paroxysmal AF, maintenance of sinus rhythm. [Keywords:] metoprolol, hypertension, atrial fibrillation (AF Paroxysmal AF is clinically one of the most common arrhythmia, ischemic stroke and risk factors of heart failure. In recent years, valvular disease significantly reduced due to AF, hypertension, valvular disease caused by non-AF AF accounted for half of the patients [1], the 2006 International AF AF treatment guidelines presented in the five clinical common cause disease [2], hypertension accounted for first, followed by coronary heart disease, heart failure, valvular disease, diabetes. Holter is the detection of paroxysmal AF effective means of clinical efficacy of metoprolol is definitely a step-down of ventricular rate control drugs and medicines [3]. now on 30 patients treated with metoprolol hypertension in patients with paroxysmal AF treated for 12 months report on follow-up